Drugs / VAL-413
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04337177 | Oct 2021 → Jun 2026 overdue | Ewing sarcoma, hepatoblastoma, medulloblastoma, neuroblastoma +1 | Valent Technologies, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VAL-413 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04337177 ↗ |